LEONARD S. SCHLEIFER, M.D., PH.D. - Corporate Board Profile

REGENERON PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2016-04-26	LEONARD S. SCHLEIFER, M.D., Ph.D., 63, co-founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. With more than 25 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry. Dr. Schleifer's significant industry and leadership experience, as well as his extensive knowledge of the Company, led the board to conclude that Dr. Schleifer should serve as a director.
2018-04-23	Leonard S. Schleifer, M.D., Ph.D. Founder, President and Chief Executive Officer Dr. Schleifer founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Regeneron's founding scientist, Dr. Yancopoulos, built and has managed the Company over the past 30 years. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. With 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry. Dr. Schleifer's significant industry and leadership experience, as well as his extensive knowledge of the Company, led the board to conclude that Dr. Schleifer should serve as a director.
2019-04-26	Dr. Schleifer founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. ... Board and Committee Membership — 2018 Attendance: Board of Directors 5/5, Technology Committee 3/3. Excludes one board meeting held solely in executive session.
2021-04-23	Dr. Schleifer founded the Company in 1988, has been a director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Regeneron's founding scientist, Dr. Yancopoulos, built and has managed the Company over the past 33 years. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. With over 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry. Dr. Schleifer's significant industry and leadership experience, as well as his extensive knowledge of the Company, led the board to conclude that Dr. Schleifer should serve as a director. Board and Committee Membership—2020 Attendance: Board of Directors: 10/11 Technology Committee: 3/3 Prior Voting Results—2019: For: 83.8% Against: 16.2% Regeneron Securities Beneficially Owned as of April 13, 2021: Class A Stock: 1,726,565 Common Stock: 580,347 Options: 1,632,488
2022-04-21	Leonard S. Schleifer, M.D., Ph.D. Director since: 1988 Age: 69 Board and Committee Membership–2021 Attendance Board of Directors: 8/9 Technology Committee Regeneron Securities Beneficially Owned: Class A Stock: 1,726,565 Common Stock: 683,074 Options: 799,616 Director Compensation Table: Leonard S. Schleifer, M.D., Ph.D. Total: 6,470,514
2024-04-25	Leonard S. Schleifer, M.D., Ph.D. - Director since 1988, Age 71. Board co-Chair since June 2023. President and CEO since inception. Compensation: $8,184,338.